Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia

NCT03008616 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03008616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
April 12, 2017
Completion date
August 13, 2020
Enrollment
58 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

severe preeclampsia